[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2024; 8: (7) ; 10.12208/j.ijcr.20240246 .

Bibliometric and visual analysis of citespace iron metabolism and liver disease
基于citespace铁代谢与肝脏疾病相关性研究的文献计量和可视化分析

作者： 马笑盈, 毛孝周, 郑盛 *, 杨涓, 王鑫鑫, 马驰, 罗江焰, 付新年

大理大学第二附属医院（云南省第三人民医院） 云南昆明

*通讯作者： 郑盛,单位：大理大学第二附属医院（云南省第三人民医院） 云南昆明；

引用本文: 马笑盈, 毛孝周, 郑盛, 杨涓, 王鑫鑫, 马驰, 罗江焰, 付新年 基于citespace铁代谢与肝脏疾病相关性研究的文献计量和可视化分析[J]. 国际临床研究杂志, 2024; 8: (7) : 20-26.
Published: 2024/7/24 11:05:23

摘要

目的 本研究以Web of Science（WOS）数据库中期刊论文为数据基础，采用Citespace6.3.R1软件对铁代谢与肝脏疾病相关性进行可视化分析，探索该领域2014年至2024年的发文情况、研究热点及动态前沿，为该领域研究方向提供参考。方法 利用文献可视化分析工具Citespace6.3.R1，对2014年1月1日至2024年1月1日在WOS数据库中检索到的铁代谢、肝脏疾病相关文献（综述或论著）进行可视化分析，并绘制可视化图谱。结果 通过文献检索共获得859篇文献，结果表明，铁代谢与肝脏疾病的文献计量呈上升趋势，通过关键词聚类生成13个图谱，聚类结果显示研究集中在hereditary hemochromatosis（遗传性血色素沉着症）、nonalcoholic fatty liver disease（非酒精性脂肪肝）、fatty liver disease（酒精性脂肪肝）、iron mètabolism（铁代谢）等领域。结论 本研究依托Citespace6.3.R1，对铁代谢与肝脏疾病的相关性进行可视化分析，揭示了该领域的研究前景，特别是铁代谢异常在肝脏疾病发生、发展中的作用。

关键词： 肝脏；铁代谢；可视化分析；Citespace6.3.R1

Abstract

Objective Based on the journal papers in the Web of Science (WOS) database, this study used Citespace6.3.R1 software to visually analyze the correlation between iron metabolism and liver diseases, and explored the published papers, research hotspots and dynamic frontiers in this field from 2014 to 2024. It provides reference for the research direction in this field.
Methods The literature related to iron metabolism and liver diseases retrieved from WOS database from January 1, 2014 to January 1, 2024 was visually analyzed using the literature visualization analysis tool Citespace6.3.R1, and the visualization map was drawn.
Results A total of 859 literatures were obtained through literature search. The results showed that the literature metrology of iron metabolism and liver diseases showed an increasing trend, and 13 maps were generated by keyword clustering. The clustering results showed that the research focused on hereditary hemochromatosis, nonalcoholic fatty liver disease and fatty liver disease (alcoholic fatty liver disease), iron metabolism (iron metabolism) and other fields.
Conclusion   This study relies on Citespace6.3.R1 to visually analyze the correlation between iron metabolism and liver diseases, revealing the research prospect in this field, especially the role of abnormal iron metabolism in the occurrence and development of liver diseases.

Key words： Liver; Iron metabolism; Visual analysis; Citespace6.3. R1

参考文献 References

[1] Kowdley K V , Brown K E , Ahn J ,et al.ACG Clinical Guideline: Hereditary Hemochromatosis[J].The American Journal of Gastroenterology, 2019, 114(8):1.

[2] Mohamed M , Phillips J .Hereditary haemochromatosis: BMJ Practice[J].Bmj, 2016:i3128.

[3] Crownover B K , Covey C J .Hereditary hemochromatosis. [J].American Family Physician, 2013(3):87.

[4] Sandnes M , Ulvik R J , Vorland M ,et al. Hyperferritinemia —A Clinical Overview[J].Journal of Clinical Medicine, 2021, 10(9):2008.

[5] Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022; 139(20):3018-3029. 

[6] Pimpin L , Cortez-Pinto H , Negro F ,et al.Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies[J]. Journal of Hepatology, 2018:S0168827818320579.

[7] Wang S , Liu Z , Geng J ,et al.An overview of ferroptosis in non-alcoholic fatty liver disease[J].Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie, 2022: 153.

[8] A J T , A D L , C H M ,et al.Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease[J].药学学报:英文版, 2022, 12(9):17.

[9] Shu YY, Gao WK, Chu HK, Yang L, Pan XL, Ye J. Attenuation by Time-Restricted Feeding of High-Fat and High-Fructose Diet-Induced NASH in Mice Is Related to Per2 and Ferroptosis. Oxid Med Cell Longev. 2022 Oct 15;2022:8063897. 

[10] Luis C B , Leon A .The Natural Course of Non-Alcoholic Fatty Liver Disease[J].International Journal of Molecular Sciences, 2016, 17(5).

[11] Loomba R , Adams L .The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.[J].Hepatology (Baltimore, Md.), 2019, 70(6):1885-1888.

[12] A M J , B H Z , A Q Q ,et al.Ferroptosis as a new therapeutic opportunity for nonviral liver disease[J].European Journal of Pharmacology, 2021.

[13] Yan H F , Zou T , Tuo Q Z ,et al.Ferroptosis: mechanisms and links with diseases[J].Signal Transduction and Targeted Therapy, 2021, 6(1):49.

[14] Chen J , Li X , Ge C ,et al.The multifaceted role of ferroptosis in liver disease[J].Cell death and differentiation, 2022(3):29.

[15] Santoro MM. The Antioxidant Role of Non-mitochondrial CoQ10: Mystery Solved! Cell Metab. 2020 Jan 7;31(1):13-15. 

[16] Xu R, Wang W, Zhang W. Ferroptosis and the bidirectional regulatory factor p53. Cell Death Discov. 2023 Jun 29;9(1):197.

[17] Asrani S K , Devarbhavi H , Eaton J ,et al.Burden of liver diseases in the world[J].Journal of hepatology, 2019, 70(1):151-171.

[18] You Y, Liu C, Liu T, et al. FNDC3B protects steatosis and ferroptosis via the AMPK pathway in alcoholic fatty liver disease. Free Radic Biol Med. 2022;193(Pt 2):808-819. 

[19] Chapman RW, Morgan MY, Boss AM, Sherlock S. Acute and chronic effects of alcohol on iron absorption. Dig Dis Sci. 1983 Apr;28(4):321-7. 

[20] Ricardo U. Macías-Rodríguez,María Eugenia Inzaugarat, Astrid Ruiz-Margáin,et al. Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis—A Novel Form of Non-Apoptotic Cell Death?[J].International Journal of Molecular Sciences, 2020, 21(5):1651-.

[21] Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012 Jan;55(1):77-85.

[22] Fujita N, Takei Y. Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J Gastroenterol. 2007 Nov;42(11):923-6. 

[23] Batsaikhan B, Gantumur G, Huang CI, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL, Lee JC, Dai CY. Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. J Chin Med Assoc. 2019 Feb;82(2):99-104.

[24] Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat Mon. 2014 Nov 1;14(11):e21184. 

[25] Tornai D, Antal-Szalmas P, Tornai T, Papp M, Tornai I, Sipeki N, Janka T, Balogh B, Vitalis Z. Abnormal ferritin levels predict development of poor outcomes in cirrhotic outpatients: a cohort study. BMC Gastroenterol. 2021 Mar 2;21(1):94. 

[26] Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X, Yu L, Li L, Ruan K, Hu H, Huang Y, Hui L, Xie D, Wang F, Hu R. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014 Apr 10;7(1):180-93.

[27] Recalcati S, Correnti M, Gammella E, Raggi C, Invernizzi P, Cairo G. Iron Metabolism in Liver Cancer Stem Cells. Front Oncol. 2019 Mar 19;9:149.